NCT00808639 - Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2013

Study Completion Date

September 30, 2016

Conditions

Bladder CancerMuscle-invasive Bladder Cancer

Interventions

DRUG

Methotrexate

intravenously 30mg/m2 over 30 minutes

DRUG

Doxorubicin

intravenously 30mg/ms over 15 minutes

DRUG

vinblastine

intravenously 3mg/m2 over 30 minutes

DRUG

cisplatin

intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion

DRUG

Pegfilgrastim

Given subcutaneously 24 hours after last chemotherapy dose

Trial Locations (4)

University of Pittsburgh Cancer Institute, Pittsburgh

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Lahey Clinic, Burlington